1
|
Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin. Cancer Gene Ther 2022; 29:908-917. [PMID: 34426652 PMCID: PMC9293752 DOI: 10.1038/s41417-021-00379-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 07/12/2021] [Accepted: 08/10/2021] [Indexed: 12/11/2022]
Abstract
Angiogenesis, the formation of new blood vessels from preexisting ones, is crucial for tumor growth and metastatization, and is considered a promising therapeutic target. Unfortunately, drugs directed against a specific proangiogenic growth factor or receptor turned out to be of limited benefit for oncology patients, likely due to the high biochemical redundancy of the neovascularization process. In this scenario, multitarget compounds that are able to simultaneously tackle different proangiogenic pathways are eagerly awaited. UniPR1331 is a 3β-hydroxy-Δ5-cholenic acid derivative, which is already known to inhibit Eph-ephrin interaction. Here, we employed an analysis pipeline consisting of molecular modeling and simulation, surface plasmon resonance spectrometry, biochemical assays, and endothelial cell models to demonstrate that UniPR1331 directly interacts with the vascular endothelial growth factor receptor 2 (VEGFR2) too. The binding of UniPR1331 to VEGFR2 prevents its interaction with the natural ligand vascular endothelial growth factor and subsequent autophosphorylation, signal transduction, and in vitro proangiogenic activation of endothelial cells. In vivo, UniPR1331 inhibits tumor cell-driven angiogenesis in zebrafish. Taken together, these data shed light on the pleiotropic pharmacological effect of UniPR1331, and point to Δ5-cholenic acid as a promising molecular scaffold for the development of multitarget antiangiogenic compounds.
Collapse
|
2
|
Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis. Oncogene 2017; 36:6531-6541. [PMID: 28783175 DOI: 10.1038/onc.2017.243] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Revised: 05/30/2017] [Accepted: 06/12/2017] [Indexed: 01/18/2023]
Abstract
Vascular endothelial growth factor receptor-2 (VEGFR2) is the main pro-angiogenic receptor expressed by endothelial cells (ECs). Using surface plasmon resonance, immunoprecipitation, enzymatic digestion, immunofluorescence and cross-linking experiments with specific sugar-binding lectins, we demonstrated that VEGFR2 bears both α,1-fucose and α(2,6)-linked sialic acid (NeuAc). However, only the latter is required for VEGF binding to VEGFR2 and consequent VEGF-dependent VEGFR2 activation and motogenic response in ECs. Notably, downregulation of β-galactoside α(2,6)-sialyltransferase expression by short hairpin RNA transduction inhibits VEGFR2 α(2,6) sialylation that is paralleled by an increase of β-galactoside α(2,3)-sialyltransferase expression. This results in an ex-novo α(2,3)-NeuAc sialylation of the receptor that functionally replaces the lacking α(2,6)-NeuAc, thus allowing VEGF/VEGFR2 interaction. In keeping with the role of VEGFR2 sialylation in angiogenesis, the α(2,6)-NeuAc-binding lectin Sambucus nigra (SNA) prevents VEGF-dependent VEGFR2 autophosphorylation and EC motility, proliferation and motogenesis. In addition, SNA exerts a VEGF-antagonist activity in tridimensional angiogenesis models in vitro and in the chick-embryo chorioallantoic membrane neovascularization assay and mouse matrigel plug assay in vivo. In conclusion, VEGFR2-associated NeuAc plays an important role in modulating VEGF/VEGFR2 interaction, EC pro-angiogenic activation and neovessel formation. VEGFR2 sialylation may represent a target for the treatment of angiogenesis-dependent diseases.
Collapse
|
3
|
De A, De A, Papasian C, Hentges S, Banerjee S, Haque I, Banerjee SK. Emblica officinalis extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors. PLoS One 2013; 8:e72748. [PMID: 24133573 PMCID: PMC3794841 DOI: 10.1371/journal.pone.0072748] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Accepted: 07/12/2013] [Indexed: 12/12/2022] Open
Abstract
Patients with ovarian cancer (OC) may be treated with surgery, chemotherapy
and/or radiation therapy, although none of these strategies are very effective.
Several plant-based natural products/dietary supplements, including extracts
from Emblicaofficinalis (Amla), have
demonstrated potent anti-neoplastic properties. In this study we determined that
Amla extract (AE) has anti-proliferative effects on OC cells under both
in vitro and in vivo conditions. We also
determined the anti-proliferative effects one of the components of AE,
quercetin, on OC cells under in vitro conditions. AE did not
induce apoptotic cell death, but did significantly increase the expression of
the autophagic proteins beclin1 and LC3B-II under in vitro
conditions. Quercetin also increased the expression of the autophagic proteins
beclin1 and LC3B-II under in vitro conditions. AE also
significantly reduced the expression of several angiogenic genes, including
hypoxia-inducible factor 1α (HIF-1α) in OVCAR3 cells. AE acted synergistically
with cisplatin to reduce cell proliferation and increase expression of the
autophagic proteins beclin1 and LC3B-II under in vitro
conditions. AE also had anti-proliferative effects and induced the expression of
the autophagic proteins beclin1 and LC3B-II in mouse xenograft tumors.
Additionally, AE reduced endothelial cell antigen – CD31 positive blood vessels
and HIF-1α expression in mouse xenograft tumors. Together, these studies
indicate that AE inhibits OC cell growth both in vitro and
in vivo possibly via inhibition of angiogenesis and
activation of autophagy in OC. Thus AE may prove useful as an alternative or
adjunct therapeutic approach in helping to fight OC.
Collapse
Affiliation(s)
- Alok De
- Department of OB/GYN, School of Medicine, University of Missouri Kansas
City, Kansas City, Missouri, United States of America
- * E-mail:
| | - Archana De
- Cancer Research Unit, VA Medical Center, Kansas City, Missouri, United
States of America
| | - Chris Papasian
- Department of Basic Medical Science, School of Medicine, University of
Missouri Kansas City, Kansas City, Missouri, United States of
America
| | - Shane Hentges
- Department of Biomedical Sciences, Colorado State University, Fort
Collins, Colorado, United States of America
| | - Snigdha Banerjee
- Cancer Research Unit, VA Medical Center, Kansas City, Missouri, United
States of America
- Division of Hematology and Oncology, Department of Medicine, University
of Kansas Medical Center, Kansas City, Kansas, United States of
America
| | - Inamul Haque
- Cancer Research Unit, VA Medical Center, Kansas City, Missouri, United
States of America
- Division of Hematology and Oncology, Department of Medicine, University
of Kansas Medical Center, Kansas City, Kansas, United States of
America
| | - Sushanta K. Banerjee
- Cancer Research Unit, VA Medical Center, Kansas City, Missouri, United
States of America
- Division of Hematology and Oncology, Department of Medicine, University
of Kansas Medical Center, Kansas City, Kansas, United States of
America
- Department of Anatomy and Cell Biology, University of Kansas Medical
Center, Kansas City, Kansas, United States of America
| |
Collapse
|
4
|
Bahramsoltani M, Plendl J. Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis. APMIS 2007; 115:30-46. [PMID: 17223849 DOI: 10.1111/j.1600-0463.2007.apm_405.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Angiogenesis, i.e. sprouting of new vessels, their remodelling and regression, is a prerequisite for growth and differentiation of organs and tissues. It is involved in many pathological processes, particularly growth and metastasis of tumours. Angiostatic therapy is a promising new strategy in the treatment of cancer. Angiogenesis inhibitors could intervene in the different phases of the angiogenic cascade, i.e. migration, proliferation, differentiation and three-dimensional organisation of endothelial cells, to inhibit the generation of tumour vessels. The aim of this study was to explore whether in a previously validated in vitro model for quantitation of angiogenesis the effects of the angiostatic factors angiostatin and suramin can be investigated and quantified. Examination of angiostatin and suramin showed that angiostatin-induced antiangiogenesis resulted in inverse angiogenesis. The addition of suramin initially resulted in increased angiogenesis. However, long-term incubation ultimately led to disintegration of endothelial structures, thus establishing the angiostatic effects of suramin. Antiangiogenesis was not only quantified using the previously validated method. It also lent itself to assessment of the extent of antiangiogenesis within the various phases of the angiogenic cascade. This method may therefore be employed in trial studies of potential angiostatic substances and related cellular mechanisms.
Collapse
|
5
|
Murata N, Yamaji T, Uchida M, Tsuboi H, Suzuki H, Yamada M, Oikawa T, Nobuhiro J, Choshi T, Hibino S. Suppression of Laser-Induced Choroidal Neovascularization by Subconjunctival Injection of 9.ALPHA.-Fluoromedroxyprogesterone Acetate (FMPA), an Anti-angiogenic Agent, in Rats. Biol Pharm Bull 2006; 29:2410-4. [PMID: 17142973 DOI: 10.1248/bpb.29.2410] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
9alpha-Fluoromedroxyprogesterone acetate (FMPA) is a synthetic analog of medroxyprogesterone acetate (MPA). FMPA exhibited more potent anti-tumor and anti-angiogenic activities in some assay systems than the parent agent, MPA. Exudative age-related macular degeneration (AMD) is characterized by choroidal neovascularization (CNV). Anecortave acetate, an angiostatic steroid, is clinically efficacious in patients with exudative AMD. Betamethasone is an anti-angiogenic steroid. Therefore, we examined the effects of FMPA, anecortave acetate and betamethasone on laser-induced CNV in rats. Anecortave acetate and betamethasone were included as positive controls. Crypton laser was applied to the fundus in Brown Norway rats. Laser photocoagulations were performed in each eye between the major retinal vessels of the superior retina. Subconjunctival injection of FMPA, anecortave acetate or betamethasone was performed once just after the photocoagulation (on day 0). The incidence of CNV formation was evaluated by fluorescein angiography (FAG) on day 14. On the next day, examination of the retinal function was performed by electro retinogram (ERG). Subconjunctival injection of FMPA at doses of 300, 1000 and 3000 microg/eye dose-dependently inhibited the incidence of CNV formation. Significant differences were observed at doses of 1000 and 3000 microg/eye of FMPA as compared with the control group. Anecortave acetate and betamethasone significantly inhibited the incidence of CNV formation. FMPA at the doses used in this study did not affect the retinal function in rats, as determined by ERG. FMPA appeared to be effective in a rat model of CNV, so it was demonstrated that FMPA might be useful in the treatment of AMD.
Collapse
Affiliation(s)
- Natsuko Murata
- Pharmaceuticals Development Department, Meiji Dairies Corporation, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Naim R, Chang RC, Sadick H, Bayerl C, Bran G, Hormann K. Effect of Vascular Endothelial Growth Factor on Fibroblasts from External Auditory Canal Cholesteatoma. Arch Med Res 2005; 36:518-23. [PMID: 16099332 DOI: 10.1016/j.arcmed.2005.03.042] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2004] [Accepted: 03/11/2005] [Indexed: 11/27/2022]
Abstract
BACKGROUND EACC is a disease of the external auditory canal resulting in destruction of adjacent tissue. However, the role of the surrounding mesenchymal fibroblasts of the perimatrix still remains unclear. In this study we treat isolated fibroblasts of EACC with VEGF and determine FGF-2 levels. We also treat the fibroblast cultures with FGF-2 and measured VEGF levels. METHODS All EACC cell cultures were obtained from five patients undergoing surgery and used at passage 3. After 1-4 days incubation with 50 ng/mL FGF-2, and 1-8 days incubation with 50 pg/mL VEGF incubation, the expression of the FGF-2 and VEGF protein in the supernatants of the HGF/SF-treated and -untreated culture cell lines was analyzed, respectively. RESULTS After 8 days of incubation with 50 ng/mL VEGF, the levels of FGF-2 decreased. However, after 4 days of incubation with FGF-2 the VEGF levels increased significantly in treated tissue culture (p <0.05) in comparison to untreated EACC fibroblasts. The total protein concentration showed no significant difference in both cultures (p >0.05). CONCLUSIONS In summary, exogenous FGF-2 increased fibroblast expression of VEGF, which is a major autocrine mediator of FGF-2-induced angiogenesis and proliferation. However, incubation with VEGF resulted in decrease of FGF-2 levels. Regarding the slow growth of the fibroblasts, they may not be as likely to exhibit a reactive or invasive phenotype as seen in middle ear cholesteatoma fibroblasts.
Collapse
Affiliation(s)
- Ramin Naim
- Department of Otolaryngology, Head and Neck Surgery, University Hospital Mannheim, Germany.
| | | | | | | | | | | |
Collapse
|
7
|
Srivastava A, Ralhan R, Kaur J. Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc Res Tech 2003; 60:208-24. [PMID: 12539175 DOI: 10.1002/jemt.10259] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Neovacularization is an essential step in the multistage progression of malignant melanoma. The onset of new blood vessel formation is ushered in by the release of VEGF and numerous other angiogenic molecules by the tumor cells. Human melanoma is unique among neoplasms that both avascular (early horizontal growth phase characterized by very slow progression and 99%, 10-year survival) and vascular (late radial and vertical growth phase associated with rapid growth, metastasis and death in many cases), phases are discernible by the naked eye. Although cell biologists have made great strides in unraveling the mechanisms involved in the laying down of tumor vasculature and the factors that inhibit it, clinicians treating melanoma have been rather slow to realize and utilize the full potential of suppressing the tumor blood flow to the best advantage of the patient. We suggest a consorted endeavor by all the melanoma experts across the globe to establish an "angiogenesis database" wherein they pool the blood flow and vascularity information along with Breslow's thickness, Clark's level of invasion, lymphatic and vascular invasion, regression, and outcome of their patients.
Collapse
Affiliation(s)
- Anurag Srivastava
- Department of Surgical Discipline, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, India.
| | | | | |
Collapse
|
8
|
Aoki K, Watanabe K, Sato M, Ikekita M, Hakamatsuka T, Oikawa T. Effects of rhizoxin, a microbial angiogenesis inhibitor, on angiogenic endothelial cell functions. Eur J Pharmacol 2003; 459:131-8. [PMID: 12524138 DOI: 10.1016/s0014-2999(02)02853-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Our previous study revealed that rhizoxin ([1S-[1R*,3R*,5S*,8R*(1R*,2S*,3E,5E,7E),10R*,11S*,13S*,14E,16S*,17S*]]-10-hydroxy-8-[2-methoxy-1,3,7-trimethyl-8-(2-methyl-4-oxazolyl)-3,5,7-octatrienyl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]heneicos-14-ene-6,19-dione) has a potent inhibitory effect on in vivo angiogenesis. However, little is known regarding the mechanism by which rhizoxin exhibits antiangiogenic activity. In this study, we examined its effects on the functions of endothelial cells associated with neovascular formation in vivo, using cultured vascular endothelial cells. Rhizoxin concentration-dependently inhibited the proliferation of bovine carotid artery endothelial cells, human umbilical vein endothelial cells and human dermal microvascular endothelial cells, the IC(50) values being 7, 5 and 0.4 nM, respectively. In addition, it reduced the extracellular plasminogen activator level in bovine vascular endothelial cells in the low nM range, and suppressed the migration of human dermal microvascular endothelial cells in the pM range. Furthermore, it blocked the tubular morphogenesis of human umbilical vein endothelial cells and human dermal microvascular endothelial cells on Matrigel in a concentration-dependent manner; the IC(50) values being 40 and 130 pM, respectively. These results suggest that rhizoxin exhibits antiangiogenic activity through the combined inhibition of some functions of endothelial cells responsible for induction of in vivo angiogenesis.
Collapse
Affiliation(s)
- Kazumasa Aoki
- Medical Research and Development Center, The Tokyo Metropolitan Institute of Medical Science (Rinshoken), Tokyo Metropolitan Organization for Medical Research, 3-18-22 Honkomagome, Tokyo 113-8613, Bunkyo, Japan
| | | | | | | | | | | |
Collapse
|
9
|
Bajou K, Lewalle JM, Martinez CR, Soria C, Lu H, Noël A, Foidart JM. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int J Cancer 2002; 100:501-6. [PMID: 12124797 DOI: 10.1002/ijc.10487] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
During angiogenesis, endothelial cells use uPA and PAI-1 to migrate and degrade the basement membrane surrounding capillary blood vessels. Invasive tumor cells produce a large amount of uPA that could bind uPAR present at the endothelial cell surface to facilitate their invasion. To verify this hypothesis, endothelial cells were incubated with conditioned medium (CM) from two breast cancer cell lines (MCF7 and MDA MB 231 cells). Within a short incubation period (30 min) with both CM, an increase of uPA, PAI-1 and uPA-PAI-1 complex was detected in endothelial cell layer as assessed by casein zymography, ELISA and uPA immunostaining. The extent of this enhancement was related to the levels of uPA secreted by tumor cells (high in MDA MB 231 cells and low in MCF7 cells). After 2 hr of incubation, the CM from both tumor cells upregulated uPA and PAI-1 mRNA levels in endothelial cells in a time-dependent manner. The uPA increase in the cell layer could not be attributable to an increase of uPAR level. Only the CM from highly invasive MDA MB 231 cells increased the angiogenic morphotype of endothelial cells assessed in a collagen gel. A single addition of amino-terminal fragment of uPA (ATF) was able to abolish the angiogenic effect induced by MDA MB 231 cell CM. Our data demonstrate that the interactions occurring between breast tumor cells and endothelial cells can modulate tumor angiogenesis at least by two mechanisms: an increase of uPA and PAI-1 cell surface-binding and of their expression by endothelial cells.
Collapse
Affiliation(s)
- Khalid Bajou
- Laboratory of Tumor and Development Biology, University of Liège, Tour de Pathologie (B23), Sart Tilman, Liège, Belgium
| | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Angiogenesis is a prerequisite for tumor growth and metastasis. Vascular endothelial cell proliferation, migration, and capillary formation are stimulated by angiogenic growth factors, which include the proteins vascular endothelial growth factor, basic fibroblast growth factor, and transforming growth factor-beta, and eicosanoids synthesized from n-6 fatty acids. Clinical studies have shown that angiogenesis in solid tumors relates to a poor prognosis and, in premalignant lesions, indicates potential for cancerous transformation. High-fat, n-6 fatty acid-rich diets were associated with a relatively poor prognosis in breast cancer patients; in a nude mouse model the same diet enhanced breast cancer progression, whereas n-3 fatty acids exerted suppressive effects that were associated with impaired angiogenesis. Lipoxygenase and cyclooxygenase products of n-6 fatty acid metabolism are angiogenic in in vitro assays. This activity is blocked by pharmacological inhibitors of eicosanoid biosynthesis, and one, indomethacin, suppressed n-6 fatty acid-stimulated murine mammary carcinoma growth and metastasis and tumor vascularization. Review of the experimental data suggests that selective inhibitors of eicosanoid-synthesizing enzymes and dietary intervention with n-3 fatty acids merit clinical evaluation as adjuvant therapy and chemopreventive agents.
Collapse
MESH Headings
- Angiogenesis Inhibitors/therapeutic use
- Animals
- Dietary Fats/administration & dosage
- Dietary Fats/adverse effects
- Dietary Fats/metabolism
- Eicosanoids/antagonists & inhibitors
- Eicosanoids/biosynthesis
- Endothelial Growth Factors/physiology
- Fatty Acids/administration & dosage
- Fatty Acids/adverse effects
- Fatty Acids/metabolism
- Fatty Acids, Omega-3/administration & dosage
- Fatty Acids, Omega-3/metabolism
- Fatty Acids, Omega-6
- Fatty Acids, Unsaturated/administration & dosage
- Fatty Acids, Unsaturated/adverse effects
- Fatty Acids, Unsaturated/metabolism
- Female
- Humans
- Lipoxygenase/metabolism
- Lymphokines/physiology
- Mice
- Models, Animal
- Neoplasm Metastasis
- Neoplasms/blood supply
- Neoplasms/diet therapy
- Neoplasms/drug therapy
- Neovascularization, Pathologic/diet therapy
- Neovascularization, Pathologic/drug therapy
- Neovascularization, Pathologic/etiology
- Prognosis
- Prostaglandin-Endoperoxide Synthases/metabolism
- Tumor Cells, Cultured
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
Collapse
Affiliation(s)
- D P Rose
- Division of Nutrition and Endrocrinology, American Health Foundation, Valhalla, NY 10595, USA
| | | |
Collapse
|
11
|
Affiliation(s)
- M Choy
- Laboratory of Vascular Hematology, Division of Hematology/Medical Oncology, Weill Medical College of Cornell University, New York, New York, USA
| | | |
Collapse
|
12
|
Presta M, Rusnati M, Dell'Era P, Tanghetti E, Urbinati C, Giuliani R, Leali D. Examining new models for the study of autocrine and paracrine mechanisms of angiogenesis through FGF2-transfected endothelial and tumour cells. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2001; 476:7-34. [PMID: 10949652 DOI: 10.1007/978-1-4615-4221-6_2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Angiogenesis is the process of generating new capillary blood vessels. Uncontrolled endothelial cell proliferation is observed in tumour neovascularization. Several growth factors and cytokines have been shown to stimulate endothelial cell proliferation in vitro and in vivo and among them FGF2 was one of the first to be characterised. FGF2 is a Mr 18,000 heparin-binding cationic polypeptide that induces proliferation, migration, and protease production in endothelial cells in culture and neovascularization in vivo. FGF2 interacts with endothelial cells through two distinct classes of receptors, the high affinity tyrosine-kinase receptors (FGFRs) and low affinity heparan sulfate proteoglycans (HSPGs) present on the cell surface and in the extracellular matrix. Besides experimental evidence for paracrine mode of action for FGF2, some observations raise the hypothesis that FGF2 may also play an autocrine role in endothelial cells. FGF2 may therefore represent a target for anti-angiogenic therapies. In order to assess the angiostatic potential of different classes of compounds, novel experimental models have been developed based on the autocrine and/or the paracrine capacity of FGF2.
Collapse
Affiliation(s)
- M Presta
- Department of Biomedical Sciences and Biotechnology, University of Brescia, Italy
| | | | | | | | | | | | | |
Collapse
|
13
|
Uchida M, Tsuboi H, Yamaji T, Murata N, Kohno T, Sugino E, Hibino S, Shimamura M, Oikawa T. Inhibition by 9alpha-fluoromedoroxyprogesterone acetate (FMPA) against mammary carcinoma induced by dimethylbenz[a]anthracene in rats and angiogenesis in the rabbit cornea - comparison with medroxyprogesterone acetate (MPA). Cancer Lett 2000; 154:63-9. [PMID: 10799740 DOI: 10.1016/s0304-3835(00)00375-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Medroxyprogesterone acetate (MPA) is currently used therapeutically in the treatment of mammary and endometrial carcinomas. In order to develop a more potent and useful drug, we synthesized the novel compound, 9alpha-fluoromedoroxyprogesterone acetate (FMPA), by fluorinating MPA, and we also previously reported that FMPA displays more potent anti-angiogenic activity in the chorioallantoic membrane assay than MPA. In the present study, we investigated (1) the effects of FMPA on rat mammary carcinomas induced by dimethylbenz[a]anthracene (DMBA) to determine the anti-tumor activity, (2) the effect on angiogenesis in rabbit corneal assays, and (3) compared these results with those for MPA. FMPA inhibited the growth of mammary carcinomas in a dose-dependent manner (7.5, 30 and 120 mg/kg). Almost complete involution of the carcinomas was observed at doses of 30 and 120 mg/kg. MPA also inhibited the growth of carcinomas at doses of 30 and 120 mg/kg, but no involution of carcinomas was observed even at 120 mg/kg. FMPA significantly and MPA to a lesser degree inhibited carcinogenesis at 120 mg/kg within their treatments. In rabbit corneal assays, FMPA significantly inhibited angiogenesis (IC50 value=0.085 microg/pellet). MPA also significantly inhibited angiogenesis (IC50 value=0.60 microg/pellet). From these results, we conclude that FMPA is potentially more effective in the treatment of mammary carcinomas than MPA.
Collapse
Affiliation(s)
- M Uchida
- Meiji Institute of Health Science, Meiji Milk Products Co., Ltd., 540 Naruda, Kanagawa, Odawara, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Yamaji T, Tsuboi H, Murata N, Uchida M, Kohno T, Sugino E, Hibino S, Shimamura M, Oikawa T. Anti-angiogenic activity of a novel synthetic agent, 9alpha-fluoromedroxyprogesterone acetate. Cancer Lett 1999; 145:107-14. [PMID: 10530777 DOI: 10.1016/s0304-3835(99)00239-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
9Alpha-fluoromedroxyprogesterone acetate (FMPA) is a novel synthetic analog of medroxyprogesterone acetate (MPA), widely used as therapeutic agent for breast and endometrium cancers. FMPA showed almost the same binding affinities to the progesterone and glucocorticoid receptors as MPA. In the rabbit corneal assay, FMPA, MPA and fumagillin significantly inhibited the angiogenic response induced by rat mammary tumor at doses of 0. 1, 1 and 50 microg/pellet, respectively, so FMPA showed greater anti-angiogenic activity than MPA and fumagillin. In the mouse dorsal air sac method, FMPA inhibited the mouse sarcoma 180 cell-induced angiogenesis by oral administration at a dose of 200 mg/kg. FMPA inhibited the activity of plasminogen activator (PA) in bovine endothelial cells. These results suggest that FMPA may be useful for diseases associated with angiogenesis by oral administration.
Collapse
Affiliation(s)
- T Yamaji
- Meiji Institute of Health Science, Meiji Milk Products Co., Ltd., Odawara, Kanagawa, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Kim-Schulze S, Lowe WL, Schnaper HW. Estrogen stimulates delayed mitogen-activated protein kinase activity in human endothelial cells via an autocrine loop that involves basic fibroblast growth factor. Circulation 1998; 98:413-21. [PMID: 9714091 DOI: 10.1161/01.cir.98.5.413] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Estrogen plays a significant role in protecting premenopausal women from cardiovascular disease. We have found that estradiol augments endothelial cell activities related to vascular healing and that human coronary artery and umbilical vein endothelial cells express estrogen receptors (ERs). Classically, the ER functions as a transcription factor, but the cytoplasmic targets of this genomic effect have not been defined for endothelial cells. In the present study, we examined the potential role of the mitogen-activated protein (MAP) kinases ERK1 and ERK2 as mediators of estrogen action. METHODS AND RESULTS Human umbilical vein endothelial cells were estrogen depleted by culturing in hormone-free medium for 48 hours before experiments. 17Beta-estradiol (E2) stimulated a delayed (3 hours) 5- to 7-fold induction of ERK1/2 activity requiring activation of ER and new transcription/translation. Conditioned media from cells stimulated for 3 hours with E2 induced immediate ERK1/2 activation and phosphorylation of the basic fibroblast growth factor (bFGF) receptor. Moreover, ERK1/2 activation by E2 or by conditioned media was abrogated by treatment with neutralizing anti-bFGF antibody. CONCLUSIONS These data describe an autocrine mechanism for E2 induction of ERK1/2 in HUVEC. Because our previous studies suggested that certain cardioprotective effects of estrogen are genomic in nature, the results are consistent with the hypothesis that autocrine stimulation of endothelial ERK1/2 activity by bFGF may play a role in the beneficial effects of estrogen on cardiovascular biology.
Collapse
MESH Headings
- Cells, Cultured
- Depression, Chemical
- Dose-Response Relationship, Drug
- Endothelium, Vascular/cytology
- Endothelium, Vascular/drug effects
- Endothelium, Vascular/metabolism
- Enzyme Activation/drug effects
- Estradiol/pharmacology
- Fibroblast Growth Factor 2/drug effects
- Fibroblast Growth Factor 2/metabolism
- Humans
- Mitogens/pharmacology
- Phosphorylation/drug effects
- Protein Biosynthesis/drug effects
- Protein Kinases/drug effects
- Protein Kinases/metabolism
- Receptors, Estrogen/antagonists & inhibitors
- Receptors, Estrogen/drug effects
- Receptors, Estrogen/metabolism
- Stimulation, Chemical
- Time Factors
- Transcription, Genetic/drug effects
Collapse
Affiliation(s)
- S Kim-Schulze
- Department of Pediatrics, Northwestern University Medical School and the Children's Memorial Institute for Education and Research, Chicago, Ill, USA.
| | | | | |
Collapse
|
16
|
Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, Shapiro RL, Galloway AC, Rifkin DB, Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141:1659-73. [PMID: 9647657 PMCID: PMC2132998 DOI: 10.1083/jcb.141.7.1659] [Citation(s) in RCA: 629] [Impact Index Per Article: 24.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/1998] [Revised: 05/20/1998] [Indexed: 02/08/2023] Open
Abstract
FGF-2 and VEGF are potent angiogenesis inducers in vivo and in vitro. Here we show that FGF-2 induces VEGF expression in vascular endothelial cells through autocrine and paracrine mechanisms. Addition of recombinant FGF-2 to cultured endothelial cells or upregulation of endogenous FGF-2 results in increased VEGF expression. Neutralizing monoclonal antibody to VEGF inhibits FGF-2-induced endothelial cell proliferation. Endogenous 18-kD FGF-2 production upregulates VEGF expression through extracellular interaction with cell membrane receptors; high-Mr FGF-2 (22-24-kD) acts via intracellular mechanism(s). During angiogenesis induced by FGF-2 in the mouse cornea, the endothelial cells of forming capillaries express VEGF mRNA and protein. Systemic administration of neutralizing VEGF antibody dramatically reduces FGF-2-induced angiogenesis. Because occasional fibroblasts or other cell types present in the corneal stroma show no significant expression of VEGF mRNA, these findings demonstrate that endothelial cell-derived VEGF is an important autocrine mediator of FGF-2-induced angiogenesis. Thus, angiogenesis in vivo can be modulated by a novel mechanism that involves the autocrine action of vascular endothelial cell-derived FGF-2 and VEGF.
Collapse
Affiliation(s)
- G Seghezzi
- Department of Surgery, and the Kaplan Cancer Center, New York University Medical Center, New York 10016, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Linder C, Byström P, Engel G, Auer G, Aspenblad U, Strander H, Linder S. Correlation between basic fibroblast growth factor immunostaining of stromal cells and stromelysin-3 mRNA expression in human breast carcinoma. Br J Cancer 1998; 77:941-5. [PMID: 9528838 PMCID: PMC2150112 DOI: 10.1038/bjc.1998.155] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
We examined the localization of basic fibroblast growth factor (bFGF) in a series of human breast carcinomas using immunohistochemistry. Staining was observed in tumour cells in 15 out of 54 (28%) tumours and in the adjacent stroma in 34 out of 54 (63%) tumours examined. No correlation was observed between positive staining of these two compartments. The relationship between bFGF staining and expression of the metalloprotease stromelysin-3, and between bFGF and microvessel density, was examined. A statistically significant correlation (P < 0.003) was observed between bFGF staining of the stromal compartment and high expression of stromelysin-3 (ST-3; MMP-11) metalloprotease mRNA by stromal cells. In contrast, no correlation was observed between bFGF and intratumour microvessel density (IMD). These results raise the possibility that bFGF may be involved in the induction of stromelysin-3 mRNA expression in breast cancer stroma.
Collapse
Affiliation(s)
- C Linder
- Department of Oncology-Pathology, Karolinska Institute and Hospital, Stockholm, Sweden
| | | | | | | | | | | | | |
Collapse
|
18
|
Ignar DM, Andrews JL, Witherspoon SM, Leray JD, Clay WC, Kilpatrick K, Onori J, Kost T, Emerson DL. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis 1998; 16:9-20. [PMID: 9502073 DOI: 10.1023/a:1006503816792] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Tumor establishment and metastasis are dependent on extracellular matrix proteolysis, tumor cell migration, and angiogenesis. Urokinase plasminogen activator (uPA) and its receptor are essential mediators of these processes. The purpose of this study was to investigate the effect of a recombinant human uPAR antagonist on growth, establishment, and metastasis of tumors derived from human cancer cell lines. A noncatalytic recombinant protein, consisting of amino acids 1-137 of human uPA and the CH2 and CH3 regions of mouse IgG1 (uPA-IgG), was expressed, purified, and shown to bind specifically to human uPAR and to saturate the surface of human tumor cells which express uPAR. Daily i.p. administration of uPA-IgG to nude mice extended latencies of unstaged tumors derived from Lox melanoma and SW48 colon carcinoma cells by 7.7 and 5.5 days, respectively. uPA-IgG treatment did not affect the growth of Lox or KB tumors staged to 200 mg before antagonist treatment commenced. The effect of uPA-IgG on the establishment of micrometastases was assessed in SCID mice. KB head/neck tumor cells were injected in the tail vein and allowed to seed for 48 h before initiation of daily i.p. injections of uPA-IgG for 24 days. The number of lung colonies ranged between 5 and 30% of vehicle-treated mice in two separate experiments. Furthermore, a single 800 microg dose of uPA-IgG administered 1 h prior to tail vein injection of KB cells reduced lung colony formation to just 3.5% of vehicle-treated SCID mice. These data demonstrate that antagonism of uPAR arrested metastasis and inhibited the establishment of primary tumors and micrometastases. Thus, small molecule uPAR antagonists may serve as useful adjuvant agents in combination with existing cancer chemotherapy.
Collapse
Affiliation(s)
- D M Ignar
- Department of Pharmacology, Glaxo Wellcome Research Institute, Research Triangle Park, NC 27709, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Gualandris A, Dell’Era P, Rusnati M, Giuliani R, Tanghetti E, Molinari-Tosatti MP, Ziche M, Ribatti D, Presta M. Autocrine Role of Basic Fibroblast Growth Factor (bFGF) in Angiogenesis and Angioproliferative Diseases. Angiogenesis 1998. [DOI: 10.1007/978-1-4757-9185-3_12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Damsky CH, Moursi A, Zhou Y, Fisher SJ, Globus RK. The solid state environment orchestrates embryonic development and tissue remodeling. Kidney Int 1997; 51:1427-33. [PMID: 9150454 DOI: 10.1038/ki.1997.195] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Cell interactions with extracellular matrix and with other cells play critical roles in morphogenesis during development and in tissue homeostasis and remodeling throughout life. Extracellular matrix is information-rich, not only because it is comprised of multifunctional structural ligands for cell surface adhesion receptors, but also because it contains peptide signaling factors, and proteinases and their inhibitors. The functions of these groups of molecules are extensively interrelated. In this review, three primary cell culture models are described that focus on adhesion receptors and their roles in complex aspects of morphogenesis and remodeling: the regulation of proteinase expression by fibronectin and integrins in synovial fibroblasts; the regulation of osteoblast differentiation and survival by fibronectin, and the regulation of trophoblast differentiation and invasion by integrins, cadherins and immunoglobulin family adhesion receptors.
Collapse
Affiliation(s)
- C H Damsky
- Department of Stomatology, University of California San Francisco, USA.
| | | | | | | | | |
Collapse
|
21
|
|
22
|
Klein S, Roghani M, Rifkin DB. Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. EXS 1997; 79:159-92. [PMID: 9002232 DOI: 10.1007/978-3-0348-9006-9_7] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- S Klein
- Department of Cell Biology, New York University Medical Center, New York 10016, USA
| | | | | |
Collapse
|
23
|
Bussolino F, Albini A, Camussi G, Presta M, Viglietto G, Ziche M, Persico G. Role of soluble mediators in angiogenesis. Eur J Cancer 1996; 32A:2401-12. [PMID: 9059328 DOI: 10.1016/s0959-8049(96)00390-5] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- F Bussolino
- Dipartimento di Genetica, Biologia e Chimica Medica, University of Torino, Italy
| | | | | | | | | | | | | |
Collapse
|
24
|
Seghezzi G, Marelli R, Mandriota SJ, Nolli ML, Mazzieri R, Mignatti P. Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells. J Cell Physiol 1996; 169:300-8. [PMID: 8908197 DOI: 10.1002/(sici)1097-4652(199611)169:2<300::aid-jcp9>3.0.co;2-s] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
We have previously reported that culture medium conditioned by human SK-Hep1 hepatoma cells or mouse S180 sarcoma cells induces in vitro angiogenesis and stimulates production of urokinase plasminogen activator (uPA) in vascular endothelial cells. These activities are mediated by a 3.5-10 kDa, heparin-binding peptide that upregulates endothelial cell expression of basic fibroblast growth factor (bFGF; Peverali et al., 1994, J. Cell. Physiol. 161:1-14.) We now report that SK-Hep 1 or S180 cell-conditioned medium rapidly induces a 4- to 5-fold increase in cell-bound uPA activity and in the high-affinity binding of 125I-prouPA to vascular endothelial cells. Ligand blotting and purification experiments show an equivalent increase in the synthesis of a cell surface protein corresponding to the endothelial cell uPA receptor (uPAR) on the basis of M, (45-50 kDa) and sensitivity to phosphatidylinositol-specific phospholipase C (PI-PLC). The tumor cell-conditioned media also upregulate uPAR mRNA levels in endothelial cells. Thus, the increase in uPA binding capacity of endothelial cells is mediated by an increased expression of uPAR. The uPAR-inducing activity of SK-Hep 1 or S180 cell-conditioned medium is not neutralized by antibodies to bFGF, and is associated with a peptide that has a M, higher than 10 kDa and no affinity for heparin. Therefore, it appears to be distinct from the bFGF/uPA-inducing factor secreted by the same cells, and from other heparin-binding cytokines that upregulate uPAR expression in endothelial cells.
Collapse
Affiliation(s)
- G Seghezzi
- Dipartimento di Genetica e Microbiologia, Università di Pavia, Italy
| | | | | | | | | | | |
Collapse
|
25
|
Fibroblast growth factor 2 and the protease activity of tumor cells isolated from BK virus/tat transgenic mice. ACTA ACUST UNITED AC 1996. [DOI: 10.1016/s0268-9499(96)80012-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
26
|
Affiliation(s)
- P Mignatti
- Dipartimento di Genetica e Microbiologia, Università di Pavia, Italy
| | | |
Collapse
|